Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Kalyteran tid bit, buy more, its time for the redbull,

<< Previous

Bullboard Posts

Next >>

Post by Dude51on Mar 16, 2021 10:50pm

373 Views

Post# 32814073

Kalyteran tid bit, buy more, its time for the redbull,

Alll Aboarddddd, train is a pulling out.......I sheite you not, this is when it starts to get exiting.

https://www.reddit.com/r/worldnews/comments/m64eio/new_covid_nasal_spray_reduces_viral_levels_by/?ref=share&ref_source=embed&utm_content=title&utm_medium=post_embed&utm_name=bc6931a1b1464ff9b8b9408bc74b3277&utm_source=embedly&utm_term=m64eio

GLTA

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management